The potential impact of the 13-valent conjugate pneumococcal vaccine on antibiotic resistance in pneumococci

S NzenzeUniversity of the Witwatersrand, Faculty of Health Science, Department of Science/National Research Foundation: Vaccine Preventable Diseases, Johannesburg;University of the Witwatersrand, Faculty of Health Science, Respiratory and Meningeal Pathogens Research Unit, JohannesburgCorrespondence[email protected]

, MBChB (Masters in Public Health (Health Economics), PhD student) ,

K KlugmanUniversity of the Witwatersrand, Faculty of Health Science, Respiratory and Meningeal Pathogens Research Unit, Johannesburg;Hubert Department of Global Health, Rollins School of Public Health and Division of Infectious Diseases, School of Medicine, Emory University, Atlanta, GA, USA

, BScMBChB, PhD, MMed, FRC(Path) (Professor of Global Health and Medicine) &

S MadhiUniversity of the Witwatersrand, Faculty of Health Science, Department of Science/National Research Foundation: Vaccine Preventable Diseases, Johannesburg;University of the Witwatersrand, Faculty of Health Science, Respiratory and Meningeal Pathogens Research Unit, Johannesburg

, MBCHB, Masters in Paediatrics, PhD (Professor of Vaccinology)

The potential impact of the 13-valent conjugate pneumococcal vaccine on antibiotic resistance in pneumococci

Information for

Open access

Opportunities

Help and information

Your download is now in progress and you may close this window

Login or register to access this feature

The potential impact of the 13-valent conjugate pneumococcal vaccine on antibiotic resistance in pneumococci

Citations (0)

Related research

To cite this article:

Download citation

Information for

Open access

Opportunities

Help and information

Keep up to date